CR Shuanghe: Proposed to obtain an exclusive license for Fascin protein inhibitors from NOVITA in the greater China region

36Kr was informed that CR Shuanghe announced that the board of directors agreed to the company's transfer from Novita Pharmaceuticals, Inc. through the Innovation Division. (NOVITA) obtained exclusive licenses for the development, production and commercialization of Fascin protein inhibitors in Greater China (Chinese mainland, Hong Kong, Macao and Taiwan), and used and acquired related intellectual property rights; agreed to pay a down payment of not more than US$115 million and three indication milestones. Previous studies have found that it can effectively inhibit Fascin protein to reduce tumor invasion or tumor metastasis, and can be used as a potential oral drug to control tumor metastasis in the future.